NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has signed an agreement making Rhenium the exclusive distributor of its RosettaGx Reveal thyroid cancer diagnostic in Israel.

Reveal is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.